IMDXEarningsglobenewswire

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Sentiment:Negative (30)

Summary

NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its second quarter results:

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 11, 2025 by globenewswire